Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
39 Cards in this Set
- Front
- Back
BCG: Use?
|
(1) Protection up to 7-10 years from EXTRA pulmonary TB
(2) Beneficial effect on superficial bladder cancer |
|
BCG: Contra?
|
Immunodeficient patients
|
|
BCG: Epidemiology?
|
Mass vaccination w/ BCG inappropriate if incidence rate less than 1% b/c of cost and interference w/ PPD
|
|
Tuberculosis:
General treatment strategies? 1st line agents? 2nd line? Other? |
General treatment strategies: Multidrug to prevent resistance, Active should be hospitalized and started w/ 4 anti-microbial agents
1st Line: (1) Isoniazid (2) Rifampin (3) Ethambutol (4) Streptomycin [aminglycoside] (5) Pyrazinamide 2nd Line: (1) Ethionamide [Izoniazide alt] (2) Para-amino-salicyclic acid [Ethambutol alt in <5yo] (3) Amikacin & Capreomycin [aminglycoside alt to streptomycin] (4) Cycloserine Others: (1) 2nd gen fluoroquinolones [cipro-, o-floxacin] & Spar-floxacin [3rd gen] --> MTB, MAC |
|
Isoniazid: Use?
|
(1) 1st line therapy in latent TB treatment in individuals vulnerable to miliary and meningial TB
(2) TB prophylaxis in IC (3) Close contact with ACTIVE TB |
|
1ST LINE TB DRUG
Isoniazid: Route? Distribution? Elimination? |
Route: Well absorbed orally but inhibited by antacids
Distribution: Gets into CNS Elimination: Isoniazid is prodrug activated by mycobacterium to INH, which is metabolized by acetylation [jap, chinese, and eskimo acetylate 5X faster] and then excreted by kidneys |
|
1ST LINE TB DRUG
Isoniazid: MOA/PD? Resistance? |
MOA/PD: Converted to INH by bacteria which inhibits mycolic acid [stage 1 cell wall] synthesis, Works both intra & extracellularly
Resistance: (1) High: KatG gene activates isoniazid to INH [mutation reduces activation] (2) Low: inhA codes for INH target reduce effects on cell wall synthesis |
|
1ST LINE TB DRUG
Isoniazid: AE? |
Inhibits pyridoxal phosphate [B6] kinase which causes: Effects can be reduced w/ B6 treatment
(1) Peripheral neuritis (2) Hepatotoxicity [<2%] in elderly b/c of INH conversion to hydrazine [toxic] (3) Hemolysis [in G6PD] (4) Drug induced SLE |
|
Isoniazid: DI?
|
1ST LINE TB DRUG
(1) Inhibits metabolism of phenytoin and warfarin (2) MAOI so causes tyramine reaction |
|
Rifampin:
Others subtypes? Use? |
1ST LINE TB DRUG
Other subtypes: Rifabutin, Rifapentine Use: Rifampin --> (1) 1st line therapy in active MTB (2) Latent MTB in INH intolerant (3) Atypical mycobacterium (4) ML (5) Meningocccal and staphylococcal carriers (6) Prophylaxis in exposure to meningeal H. influenzae (7) Enhance effects of amphotericin B in systemic fungal infection (8) Doxycycline + Rifampin are used in brucellosis Rifabutin --> Better MAC activity and good in HIV b/c less interaction w/ HAART, x-resistance +ve Rifapentine --> Longer acting than rifampin but, x-resistance +ve |
|
Rifampin:
MOA/PD? Resistance? |
1ST LINE TB DRUG
MOA/PD: Inhibits DNA dependent RNA pol, Effective against both intra & extracellular Resistance: (1) High: KatG gene activates isoniazid to INH [mutation reduces activation] (2) Low: inhA codes for INH target reduce effects on cell wall synthesis |
|
Rifampin: AE?
|
1ST LINE TB DRUG
(1) Hepatotoxicity (2) Body fluids colored red (3) Flu-like syndrome [fever, chills, GI irritation, skin rash] |
|
Rifampin: DI?
|
1ST LINE TB DRUG
Induces CYP450 and enhances elimination of many drugs |
|
Ethambutol: Use?
|
1st line therapy in tuberculosis
|
|
Ethambutol:
Route? Distribution? Elimination? |
1ST LINE TB DRUG
Route: Oral well absorbed Distribution: Gets in CNS Elimination: UNCHANGED in urine |
|
Ethambutol:
MOA/PD? Resistance? |
1ST LINE TB DRUG
MOA/PD: (1) Inhibits arabinosyl transferase and blocks arabinogalactan [cell wall] (2) Inhibits nucleic acids Resistance: emb gene mutation |
|
Ethambutol: AE?
|
1ST LINE TB DRUG
(1) Decreased visual acuity & optic neuritis [dose dependent and reversible] (2) Loss of ability to differentiate red from green (3) Neurotoxicity (4) May interfere w/ uric acid secretion [gouty attack] |
|
Ethambutol:
Contra? Alternative? |
1ST LINE TB DRUG
Contra: Not recommended in children under 5 Alternative: Para-aminosalicyclic acid [PAS] |
|
Pyrazinamide: Use?
|
1st line TB drug in ACTIVE infection
|
|
Pyrazinamide:
Route? Distribution? Environment of activity? Elimination? |
1ST LINE TB DRUG
Route: Good oral Distribution: CNS also Environment of activity: Active in acidic environments w/ effects up to 2mo if inflammation is present Elimination: Toxicity goes up in hepatic or renal dysfunction |
|
Pyrazinamide: AE?
|
1ST LINE TB DRUG
(1) Hepatotoxicity (2) PPP --> Porphyria, Polyarthralgia, Photosensitivity (3) GI Irritation, Skin rashes |
|
Ethionamide:
Use? MOA/PD? |
Use: 2nd line TB drug
MOA/PD: Similar action to INH [mycolic acid synth inhibitor so stage 1 cell wall synth inhib] but no x-resistance w/ INH |
|
Ethionamide:
Route? Distribution? |
2ND LINE TB DRUG
Route: Oral good Distribution: Gets to CNS |
|
Ethionamide: AE?
|
2ND LINE TB DRUG
Neurotoxic leading to: (1) Mental disturbances (2) Impotence |
|
Para aminosalicyclic acid [PAS]:
Use? Alternative to? |
Use: 2nd line TB drug
Alternative to: Ethambutol in children < 5yo |
|
Para aminosalicyclic acid [PAS]:
Distribution? MOA/PD? |
2ND LINE TB DRUG
Distribution: NO CNS MOA/PD: Blocks dihydropterate synthase [folic acid synth inhibitor] |
|
Para aminosalicyclic acid [PAS]: AE?
|
2ND LINE TB DRUG
(1) GI disturbance & pain in large doses (2) Hypersensitivity (3) Renal, thyroid, and liver dysfunctions |
|
Cycloserine: Use?
|
(1) 2nd line TB drug [strains resistant to INH, streptomycin, & PAS]
(2) MAC often susceptible (3) 2nd line against CNS nocardia [sulfa drugs 1st] |
|
Cycloserine:
Route? Distribution? Elimination? |
2ND LINE TB DRUG
Route: Oral good Distribution: CSF good Elimination: 50% excreted from kidneys unchanged |
|
Cycloserine: AE?
|
2ND LINE TB DRUG
(1) Psychosis, C/I seizures Peripheral neuropathy, Convulsions (2) Delirium, Confusion, Headache, Tremors |
|
Cycloserine: MOA/PD?
|
2ND LINE TB DRUG
Inhibits conversion of L-alanine to D-form and linkage of D-form through inhibition of alanine racemase [cell wall stage 1 inhibitor] |
|
Dapsone/Acedapsone:Use?
|
DOC's in leprocy:
(1) Acedapsone --> Repository form of dapsone & can also be as alternate in PCP infection in AIDS pts. |
|
Dapsone/Acedapsone:
AE? AE treatment/alternatives? |
DOC IN LEPROCY
AE: (1) Lepra rxn [Erythma nodosum leprosum, similar to Jarisch-Herxeimer rxn] (2) Hemolytic anemia in G6PD, Peripheral neuritis, GI irritation, Drug-induced lupus AE treatment/alternatives: Lepra rxn alternatives/treatments (1) Clofazamine is alternative [antileprotic and anti-inflammatory effects] (2) Chloroquine, thalidomide, & corticosteroids in serious cases |
|
Clofazimine: Use?
|
2nd line therapy for ML in dapsone resistant, lepra rxn, combination treatment, & pts. that cannot tolerate dapsone
|
|
Clofazimine: AE?
|
2nd LINE IN LEPROCY
(1) Eosinophilic enteritis [GI irritation] (2) DISCOLORATION of the skin |
|
Amithiozone: Use?
|
2nd line therapy [dapsone alternate] in ML, but resistance fairly common hence only used in combo w/ other anti-leprosy drugs
|
|
Stremptomycin:
Main use? Back-up drug for? Combination therapy? Spectrum? AE specific in long term use? |
AMINOGLYCOSIDE ANTIBIOTIC
Main Use: (1) 1st line drug against advanced TB [best alternate is amikacin followed by capreomycin] (2) Plague & tularemia Back-up drug for: Brucellosis Combination therapy: Very effective w/ Pen G in enterococcal infections Spectrum: Differs from other aminoglycosides in that NOT very effective against gram -ve rods AE specific in long term use? Optic nerve dysfunction |
|
Prophylaxis of MAC in AIDS?
|
Azithromycin & Clarithromycin [macrolides w/ long half lives]
|
|
Leprosy: Drugs used in order?
|
(1) Dapsone & acedapsone
(2) Clofazimine (3) Rifampin (4) Amithiozone (5) Minocycline [3rd gen tetracycline] (6) Ofloxacin [2nd gen flouroquinolone] |